Patents Assigned to CÉZANNE S.A.S.
  • Method diagnosis of a prenatal disorder by selective determination of placental growth factor 2
    Patent number: 11307209
    Abstract: The present invention relates to an immunoassay method for placental growth factor 2 (PlGF-2) detection in pregnant subjects. Furthermore the invention relates to the use of said method for the diagnosis, prognosis, risk assessment and therapy control of prenatal disorders comprising the determination of the level of PlGF-2 in said pregnant subjects.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: April 19, 2022
    Assignee: CÉZANNE S.A.S.
    Inventors: Gaïané Demirdjian, Delphine Espinasse
  • METHOD FOR THE SELECTIVE DETERMINATION OF PLACENTAL GROWTH FACTOR 2
    Publication number: 20170003304
    Abstract: The present invention relates to an immunoassay method for placental growth factor 2 (PlGF-2) detection in pregnant subjects. Furthermore the invention relates to the use of said method for the diagnosis, prognosis, risk assessment and therapy control of prenatal disorders comprising the determination of the level of PlGF-2 in said pregnant subjects.
    Type: Application
    Filed: December 3, 2014
    Publication date: January 5, 2017
    Applicant: CÉZANNE S.A.S.
    Inventors: Gaïané DEMIRDJIAN, Delphine ESPINASSE
  • MARKERS FOR THE PROGNOSIS AND RISK ASSESSMENT OF PREGNANCY-INDUCED HYPERTENSION AND PREECLAMPSIA
    Publication number: 20130177901
    Abstract: The present invention relates to the prognosis and risk assessment in pregnant women to develop pregnancy-induced hypertension and/or preeclampsia by the determination of marker levels.
    Type: Application
    Filed: June 17, 2011
    Publication date: July 11, 2013
    Applicant: CEZANNE S.A.S.
    Inventors: Bruno Darbouret, Gaiane Demirdjian
  • In Vitro Method for Diagnosing and Monitoring Metastasized Bladder Cancer Using the Determination of MMP-7 in the Circulation of Patients
    Publication number: 20100028909
    Abstract: The present invention relates to the use in diagnostic in vitro methods for the detection, early detection, monitoring and/or prognosis of metastatic bladder cancer in human patients of matrix metalloproteinase 7 (MMP-7) and/or its precursors and fragments with MMP-7 immunoreactivity that can be measured in blood, serum or plasma samples from the patient.
    Type: Application
    Filed: June 12, 2007
    Publication date: February 4, 2010
    Applicant: CEZANNE S.A.S.
    Inventors: Bruno Darbouret, Gaiané Sarkissian
  • In Vitro Method for Diagnosing and Monitoring Renal Cell Carcinoma (Rcc) Using Mmp-7 as Humoral Biomarker for Rcc
    Publication number: 20080254483
    Abstract: The present invention relates to the use of matrix metalloproteinase 7 (MMP-7) and/or its precursors and fragments with MMP-7 immunoreactivity, or of circulating anti-MMP-7 antibodies, as humoral biomarkers in diagnostic in vitro methods for the detection, early detection, monitoring and/or prognosis of renal cell carcinoma (RCC) in human patients.
    Type: Application
    Filed: August 21, 2006
    Publication date: October 16, 2008
    Applicant: CEZANNE S.A.S
    Inventors: Bruno Darbouret, Gaiane Sarkissian